Results for: C-THR81-2405 PDF Questions with A Guaranteed Success 2024 ⚒ Easily obtain free download of “ C-THR81-2405 ” by searching on ⏩ www.pdfvce.com ⏪ 🤛Exam C-THR81-2405 Format

Higher diastolic BP associated with cognitive impairment

…Higher diastolic blood pressure levels appear to be associated with impaired cognitive status, according to an analysis of subjects enrolled in the REGARDS study (Tsivgoulis et al. Neurology 2009; 73: 589-595). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…

One-third of early PD patients show cognitive decline

…A longitudinal study has examined cognitive decline in 106 patients with early Parkinson’s disease (mean age 61.2 years). Cognitive decline was assessed using the Mini Mental State Examination (MMSE; mean baseline 27.8) (Kandiah et al. Mov Disord 2009); epublished February 3, 2009. Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…

CIHR, Quebec and France collaborate on Alzheimer disease research

The Canadian Institutes of Health Research (CIHR, www.cihr-irsc.gc.ca), in conjunction with the province of Quebec and France, has launched a new funding program for innovative projects in Alzheimer’s disease research. CIHR will commit $600,000, Quebec $800,000 and France $1.1 million over the next three years to the program. A joint request for applications is currently being developed. Subscribe to read more It takes 30 seconds or login using y…

Predictors of response: results from long-term follow-up

REPORT FROM THE 2009 AAN ANNUAL MEETING – Early progression of disability, a high relapse rate and ongoing MRI activity appear to be indicators of an inadequate response to disease-modifying therapy, according to the 15-year follow-up results of the MS Collaborative Study Group pivotal trial of beta-interferon-1a (Avonex) (Bermel et al. AAN 2009; abstract P02.117). Subscribe to read more It takes 30 seconds or login using your email address Pleas…

Preliminary results of rituximab in progressive MS

…REPORT FROM THE 2009 AAN ANNUAL MEETING – Two studies have investigated the potential benefits of rituximab, a monoclonal antibody that targets CD20 B cells, in primary- and secondary-progressive MS (PPMS, SPMS). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…